<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zilocchi M</submitter><funding>National Institutes of Health</funding><funding>Canadian Institutes of Health Research</funding><funding>Parkinson Society Canada</funding><funding>NIGMS NIH HHS</funding><pagination>423</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7300190</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8</volume><pubmed_abstract>Mutations in &lt;i>PARK2&lt;/i> gene are the most frequent cause of familial forms of Parkinson's disease (PD). This gene encodes Parkin, an E3 ubiquitin ligase involved in several cellular mechanisms, including mitophagy. Parkin loss-of-function is responsible for the cellular accumulation of damaged mitochondria, which in turn determines an increment of reactive oxygen species (ROS) levels, lower ATP production, and apoptosis activation. Given the importance of mitochondrial dysfunction and mitophagy impairment in PD pathogenesis, the aim of the present study was to investigate both total and mitochondrial proteome alterations in human skin fibroblasts of &lt;i>PARK2&lt;/i>-mutated patients. To this end, both total and mitochondria-enriched protein fractions from fibroblasts of five &lt;i>PARK2&lt;/i>-mutated patients and five control subjects were analyzed by quantitative shotgun proteomics to identify proteins specifically altered by Parkin mutations (mass spectrometry proteomics data have been submitted to ProteomeXchange with the identifier PXD015880). Both the network-based and gene set enrichment analyses pointed out pathways in which Rab GTPase proteins are involved. To have a more comprehensive view of the mitochondrial alterations due to &lt;i>PARK2&lt;/i> mutations, we investigated the impact of Parkin loss on mitochondrial function and network morphology. We unveiled that the mitochondrial membrane potential was reduced in &lt;i>PARK2&lt;/i>-mutated patients, without inducing PINK1 accumulation, even when triggered with the ionophore carbonyl cyanide m-chlorophenylhydrazone (CCCP). Lastly, the analysis of the mitochondrial network morphology did not reveal any significant alterations in &lt;i>PARK2&lt;/i>-mutated patients compared to control subjects. Thus, our results suggested that the network morphology was not influenced by the mitochondrial depolarization and by the lack of Parkin, revealing a possible impairment of fission and, more in general, of mitochondrial dynamics. In conclusion, the present work highlighted new molecular factors and pathways altered by &lt;i>PARK2&lt;/i> mutations, which will unravel possible biochemical pathways altered in the sporadic form of PD.</pubmed_abstract><journal>Frontiers in cell and developmental biology</journal><pubmed_title>Exploring the Impact of &lt;i>PARK2&lt;/i> Mutations on the Total and Mitochondrial Proteome of Human Skin Fibroblasts.</pubmed_title><pmcid>PMC7300190</pmcid><funding_grant_id>R01 GM106019</funding_grant_id><pubmed_authors>Fasano M</pubmed_authors><pubmed_authors>Colugnat I</pubmed_authors><pubmed_authors>Moutaoufik MT</pubmed_authors><pubmed_authors>Zilocchi M</pubmed_authors><pubmed_authors>Alberio T</pubmed_authors><pubmed_authors>Corasolla Carregari V</pubmed_authors><pubmed_authors>Garavaglia B</pubmed_authors><pubmed_authors>Marini F</pubmed_authors><pubmed_authors>Meduri M</pubmed_authors><pubmed_authors>Phanse S</pubmed_authors><pubmed_authors>Babu M</pubmed_authors><pubmed_authors>Pieroni L</pubmed_authors><pubmed_authors>Lualdi M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring the Impact of &lt;i>PARK2&lt;/i> Mutations on the Total and Mitochondrial Proteome of Human Skin Fibroblasts.</name><description>Mutations in &lt;i>PARK2&lt;/i> gene are the most frequent cause of familial forms of Parkinson's disease (PD). This gene encodes Parkin, an E3 ubiquitin ligase involved in several cellular mechanisms, including mitophagy. Parkin loss-of-function is responsible for the cellular accumulation of damaged mitochondria, which in turn determines an increment of reactive oxygen species (ROS) levels, lower ATP production, and apoptosis activation. Given the importance of mitochondrial dysfunction and mitophagy impairment in PD pathogenesis, the aim of the present study was to investigate both total and mitochondrial proteome alterations in human skin fibroblasts of &lt;i>PARK2&lt;/i>-mutated patients. To this end, both total and mitochondria-enriched protein fractions from fibroblasts of five &lt;i>PARK2&lt;/i>-mutated patients and five control subjects were analyzed by quantitative shotgun proteomics to identify proteins specifically altered by Parkin mutations (mass spectrometry proteomics data have been submitted to ProteomeXchange with the identifier PXD015880). Both the network-based and gene set enrichment analyses pointed out pathways in which Rab GTPase proteins are involved. To have a more comprehensive view of the mitochondrial alterations due to &lt;i>PARK2&lt;/i> mutations, we investigated the impact of Parkin loss on mitochondrial function and network morphology. We unveiled that the mitochondrial membrane potential was reduced in &lt;i>PARK2&lt;/i>-mutated patients, without inducing PINK1 accumulation, even when triggered with the ionophore carbonyl cyanide m-chlorophenylhydrazone (CCCP). Lastly, the analysis of the mitochondrial network morphology did not reveal any significant alterations in &lt;i>PARK2&lt;/i>-mutated patients compared to control subjects. Thus, our results suggested that the network morphology was not influenced by the mitochondrial depolarization and by the lack of Parkin, revealing a possible impairment of fission and, more in general, of mitochondrial dynamics. In conclusion, the present work highlighted new molecular factors and pathways altered by &lt;i>PARK2&lt;/i> mutations, which will unravel possible biochemical pathways altered in the sporadic form of PD.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2024-12-03T18:15:41.859Z</modification><creation>2020-07-03T07:02:28Z</creation></dates><accession>S-EPMC7300190</accession><cross_references><pubmed>32596240</pubmed><doi>10.3389/fcell.2020.00423</doi></cross_references></HashMap>